Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome BioscienceTSE:4583 -1.43%38 Piotroski F-Score is 4 as of Jul. 25, 2026, which is at its 10-year median of 4.00. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 1,333 Biotechnology companies, Chiome Bioscience ranks better than 73.97% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Chiome Bioscience has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Chiome Bioscience's Piotroski F-Score or its related term are showing as below:
TSE:4583'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 5
Current: 4
During the past 13 years, the highest Piotroski F-Score of Chiome Bioscience was 5. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Chiome Bioscience Piotroski F-Score Related Terms
Chiome Bioscience Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Chiome Bioscience's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Chiome Bioscience's current Net Income (TTM) was -982.8.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Chiome Bioscience's return on assets of this year was -0.39807044. Chiome Bioscience's return on assets of last year was -0.58281633.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Chiome Bioscience's gearing of this year was 0.0834056. Chiome Bioscience's gearing of last year was 0.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Chiome Bioscience's current ratio of this year was 4.12579324. Chiome Bioscience's current ratio of last year was 4.73757681.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Chiome Bioscience's number of shares in issue this year was 56.031. Chiome Bioscience's number of shares in issue last year was 58.208.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Chiome Bioscience's gross margin of this year was 0.59934096. Chiome Bioscience's gross margin of last year was 0.55436221.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Chiome Bioscience's asset turnover of this year was 0.24030958. Chiome Bioscience's asset turnover of last year was 0.44580617.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
0
+
0
+
1
+
1
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Chiome Bioscience has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Chiome Bioscience (TSE:4583) has a Piotroski F-Score of 4 as of Jul. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chiome Bioscience and its competitors. This is near median its historical median of 4.00. Over the past decade, Chiome Bioscience's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, Chiome Bioscience ranks #347 out of 1333 companies in the Biotechnology industry, placing it in the top 26%.
Is Chiome Bioscience's Piotroski F-Score too high?
Chiome Bioscience's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Chiome Bioscience's value of 4 is 33.3% above this industry median. Based on the distribution chart, Chiome Bioscience ranks #347 out of 1333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #347 out of 1333 companies for Piotroski F-Score. This puts Chiome Bioscience in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Chiome Bioscience's value of 4 is 33.3% above this benchmark. Historically, Chiome Bioscience's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Chiome Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiome Bioscience's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Piotroski F-Score is 4 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02.
GuruFocus considers Chiome Bioscience to be Possible Value Trap.
Key valuation signals for TSE:4583:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
Industry Position: 33.3% above the Biotechnology median (#347 of 1333)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score
Get the complete analysis for TSE:4583
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
